Loading clinical trials...

Macula Evolution in Patients With AMD Taking Oral Food Supplementation | Clinical Trials | Clareo Health

COMPLETEDNA

Macula Evolution in Patients With AMD Taking Oral Food Supplementation

Macular Drusen Evolution in Patients With Intermediate Age-related Macular Degeneration (AMD) Taking Oral Food Supplementation: an Open-label,Single-arm Pilot Study

NCT04778436•Laboratoires Thea

View on ClinicalTrials.gov

Summary

LT7082-001 is an open-label, single-arm pilot study. Patients with intermediate age-related macular degeneration (AMD) wil take T7082 during 12 months , an association of 4 food supplementations . The study objectives are to describe morphological changes and evolution of drusen in macula after a 12-month of food supplementation and to assess the safety of T7082

Eligibility

Age

50 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Informed consent signed and dated
•Age ≥ 50 years old
•At least one Eligible Eye, defined by following conditions :
•1. Far Best Corrected Visual Acuity (BCVA) ≥ 75 ETDRS letters (or ≥ 20/32 Snellen equivalent)
•2. At least one drusen with a minimal diameter of 125 µM assessed by SD-OCT / intermediate age-related macular degeneration
•3. Macula sparing
•4. Clear ocular media
•5. Adequate pupillary dilation

Exclusion Criteria

•Presence of other macular disease such as epiretinal membrane or macular telangiectasia.
•Presence of any geographic atrophy including macular region
•Any history of retina neovascularization
•Macula or retinal diseases other than age-related macular degeneration
•A concurrent ocular pathology that may contribute to vision loss (eg, choroidal neovascularization, glaucoma, visually significant cataract, optic neuropathy, history of retinal surgery) or interfere with acquisition of high-quality images
•Ocular or periocular infections
•Presence of congenital retinal pathologies that may impact data collection
•Exudative AMD

Locations (1)

Wilfried Roquet

Clermont-Ferrand, France

Key Dates

Start Date

January 13, 2021

Primary Completion Date

January 24, 2022

Completion Date

January 24, 2022

Last Updated

February 15, 2022

Enrollment

ACTUAL participants

Conditions

Age Related Macular Degeneration

Interventions

T7082

DIETARY_SUPPLEMENT

Identification of Molecular Signals in Vitreous Humor Associated With Suboptimal Response to Vascular Endothelial Growth Factor (VEGF) Inhibition in Neovascular Age-related Macular Degeneration (nAMD) Within a Clinical Trial Setting

NCT07249216

Age Related Macular Degeneration

View study

RECRUITINGPHASE1/PHASE2

Evaluating a New Peptide Therapy for Retinal Diseases: AMD, Diabetic Retinopathy, and Dystrophies

NCT06787482

Retinitis Pigmentosa (RP)Age Related Macular Degeneration+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 15, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Macula Evolution in Patients With AMD Taking Oral Food Supplementation

Inclusion Criteria

Exclusion Criteria

Identification of Molecular Signals in Vitreous Humor Associated With Suboptimal Response to Vascular Endothelial Growth Factor (VEGF) Inhibition in Neovascular Age-related Macular Degeneration (nAMD) Within a Clinical Trial Setting

Evaluating a New Peptide Therapy for Retinal Diseases: AMD, Diabetic Retinopathy, and Dystrophies

Survival of Monocytes Collected From Patients With Atrophic AMD in Retinal Pigmented Epithelium Explants

A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56

Retinal Pigment Epithelium Safety Study for Patients in B4711001

Evaluating the Relationship Between Function and Structure in ARCHER II-like Population Using Data From a Natural History Cohort